Biotechnology

Transcenta Announces Updated Clinical Data from Phase I Study of pH-Dependent PD-L1 Antibody MSB2311 to Be Presented at the 2021 ASCO Annual Meeting

SUZHOU, China, May 14, 2021 /PRNewswire/ -- Transcenta Holding Limited (Transcenta), a clinical stage global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, today announced that the updated phase I clinical da...

2021-05-14 08:00 2591

Antengene Announces the Completion of Its Manufacturing Center in Shaoxing to Accelerate the Commercialization of Novel Anti-Cancer Therapies

SHANGHAI and HONG KONG, May 14, 2021 /PRNewswire/ -- Today, Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) successfully hosted an inauguration ceremony for its manufacturing center at the Binhai Life Science and Healthcare Industrial Zone in Shaoxing. The completion of the manufacturi...

2021-05-14 08:00 5132

An oral antiviral drug from Korea may be a problem solver for COVID-19

SEOUL, South Korea, May 13, 2021 /PRNewswire/ -- Hyundai Bioscience (KOSDAQ 048410) announced that Dr.Jin-Ho Choi, a Chief Scientist of its major shareholding bio tech company CNPharm and Chair Professor at Dankook University, presented the study titled 'COVID-19 Game Changer Drug – a novel orga...

2021-05-13 16:37 2432

Pregene and Dr. Reddy's Announce License Agreement for Anti-BCMA CAR-T PRG1801 in India

BEIJING, May 13, 2021 /PRNewswire/ -- Beijing Time May 10, 2021 — Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) and Shenzhen Pregene Biopharma Co., Ltd. today announced an agreement whereby Dr Reddy's will acquire an exclusive license in the Republic ofInd...

2021-05-13 15:21 1935

Amorepacific Discovers Skin Barrier Regulator EGR3

* At the Society for Investigative Dermatology's e-poster talk session held on the 5th, Amorepacific announced the results of its skin barrier-related research. * Amorepacific has discovered EGR3 and identified its epigenetic regulation mechanism through the analysis of big data in the bio fi...

2021-05-13 10:31 4176

Antengene Announces IND Approval in China for a Global Phase III Trial of Selinexor in Advanced or Recurrent Endometrial Cancer

SHANGHAI and HONG KONG, May 13, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncolo...

2021-05-13 08:00 3665

Discover Six Dynamic Trends to Disrupt the Next Generation of Biopharmaceutical Manufacturing

Technology, industry collaborations and a desire to innovate will help participants sustain their growth momentum and achieve manufacturing scale, finds Frost & Sullivan SANTA CLARA, Calif., May 12, 2021 /PRNewswire/ -- The biopharmaceutical industry is facing its biggest test in recent times. A...

2021-05-12 18:12 1784

Zymo Research Releases Open-Source Bioinformatics Pipeline for SARS-CoV-2 Variant Detection in Wastewater

IRVINE, Calif., May 11, 2021 /PRNewswire/ -- Zymo Research has released the VirSieve™ Bioinformatics Pipeline source code to the environmental microbiology community to promote global collaboration and support for the detection of SARS-CoV-2 variants in wastewater. VirSieve™ is an automated compu...

2021-05-11 17:05 3247

Hong Kong government endorses INDICAID(R) in visitation resumption arrangements

HONG KONG, May 11, 2021 /PRNewswire/ -- COVID-19 rapid antigen test (RAT) INDICAID®, developed by Hong Kong biotechnology start-up PHASE Scientific International Limited (PHASE), has been named by the government as one of the designated rapid tests when care homes resume visitation on Monday. The...

2021-05-11 08:00 2557

Gracell Biotechnologies Appoints Seasoned Gene & Cell Therapy Executive Dr. Jenny (Yajin) Ni as Chief Technology Officer

SUZHOU and SHANGHAI, China, May 10, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced the appoin...

2021-05-11 04:01 2950

Novavax Announces Positive Preclinical Data for Combination Influenza and COVID-19 Vaccine Candidate

- Manuscript highlights development of robust responses to both influenza and COVID-19 and protection against the SARS-CoV-2 virus - Data shared via preprint server for biology, bioRxiv, ahead of publication GAITHERSBURG, Md., May 10, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechn...

2021-05-10 21:55 4788

PharmAbcine Announces Encouraging Non-clinical Data of PMC-403 at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting

DAEJEON, South Korea, May 10, 2021 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of antibody therapeutics, announced today that the company presented an e-poster featuring non-clinical data of PMC-403 at the Association for Resea...

2021-05-10 20:00 1877

INOVIO Announces Positive Data from Phase 2 Segment of Clinical Trial Evaluating INO-4800, its COVID-19 DNA Vaccine

PLYMOUTH MEETING, Pa., May 10, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, today announced positive safety, tolerability ...

2021-05-10 20:00 4292

Viva Biotech and BioMap Reached a Strategic Collaboration Agreement, To Jointly Accelerate the Early Drug Discovery through AI Technology

SHANGHAI, May 10, 2021 /PRNewswire/ -- Hosted by BioMap and Adock, the first generation of China Biocomputing Conference was successfully launched in Suzhou. The conference is aiming to unite with biotech and IT industry partners to create a multi-party integrated industrial ecosystem, and realiz...

2021-05-10 18:21 3034

Bionomics BNC210 Expansion into Social Anxiety Disorder

* Rapid oral absorption of BNC210 novel tablet formulation ideally suited for acute treatment of anxiety in patients with Social Anxiety Disorder * BNC210 Phase 2b PTSD trial on target for start in mid-2021 with U.S. CRO Premier Research selected and clinical site identification underway * P...

2021-05-10 18:00 3775

Hong Kong government endorses INDICAID(R) in visitation resumption arrangements

HONG KONG, May 10, 2021 /PRNewswire/ -- COVID-19 rapid antigen test (RAT) INDICAID®, developed by Hong Kong biotechnology start-up PHASE Scientific International Limited (PHASE), has been named by the government as one of the designated rapid tests when care homes resume visitation today. The end...

2021-05-10 11:30 1964

New focus on male factors critical for success in human fertility treatment

SINGAPORE, May 10, 2021 /PRNewswire/ -- The adverse impact of male factors in assisted reproductive treatments was brought into a clear and disturbing focus at the 10th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE). The ASPIRE Congress, originally to be held in the Philippine...

2021-05-10 10:06 1677

Hong Kong government endorses INDICAID(R) in visitation resumption arrangements

HONG KONG, May 10, 2021 /PRNewswire/ -- COVID-19 rapid antigen test (RAT) INDICAID®, developed by Hong Kong biotechnology start-up PHASE Scientific International Limited (PHASE), has been named by the government as one of the designated rapid tests when care homes resume visitation today. The end...

2021-05-10 10:00 2149

Alebund Pharmaceuticals Raises $60 million in Series B Financing Round to Accelerate Its Development of Innovative Drugs and Total Solutions for the Treatment of Renal Diseases

SHANGHAI, May 9, 2021 /PRNewswire/ -- Alebund Pharmaceuticals ("Alebund" or the "Company"), a biopharmaceutical company dedicated to developing innovative therapies for the treatment of renal diseases and related chronic conditions, today announced that it has raised$60 million in its Series B fi...

2021-05-10 08:13 1859

Daewoong showed improved performance both sales and earnings in Q1

* OP. income exceeded 20 billion won due to successful export of Fexuprazan and sales recovery * Nabota(botulinum toxin) revenue soared after settlement, historical high performance in March * Turnaround in earnings just started and will continue to 2H SEOUL, South Korea, May 7, 2021 /PRNew...

2021-05-07 21:00 5280
1 ... 330331332333334335336 ... 344